Product Reports Resources Pricing Login Book a demo

Changzhou Boyi Biotechnology

Health · China

Raw materials and solutions for in-vitro diagnostics MoreLess

Changzhou Boyi Biotechnology Co., Ltd. is a technology-focused enterprise centered on the in-vitro diagnostic industry. The company originated in 2013 as Changzhou Tiandi Renhe Biotechnology Co., Ltd., founded by a group of experts in polymer materials, proteomics, and molecular biology to focus on the purification of biological macromolecules. The Boyi Bio Group itself was established in 2022 and now owns brands such as Tiandi Renhe, Boyi Bio, and ACE. The chairman and general manager is Fang Li.

Boyi Biotechnology provides key raw materials and integrated solutions for biomedical clients. The business is structured around three main sectors: purification of biological macromolecules, core raw materials for in-vitro diagnostic reagents, and life science research reagents. The company's product lines include diagnostic microspheres, testing raw materials, and quality control products. Specifically, they produce a range of chromatography resins (gel filtration, affinity, ion exchange, hydrophobic interaction), magnetic beads, and various biological reagents and instruments under its ACE brand. These products are used in applications such as recombinant proteins, vaccines, antibodies, gene therapy, and cell therapy.

The company has made significant investments in its infrastructure, with a total project investment of RMB 300 million for a 45,000-square-meter facility in Changzhou's Xitaihu Industrial Park, which includes R&D, office, and production buildings with 10 automated production lines expected to be operational in the second half of 2024. Boyi Biotechnology has received recognition as a National High-tech Enterprise in 2019 and was named a provincial "Potential Unicorn" and "Gazelle" enterprise. As of early 2024, the company holds 6 authorized invention patents and 62 utility model patents. In July 2023, it successfully obtained ISO 13485:2016 certification for its medical device quality management system.

Keywords: in-vitro diagnostics, biological raw materials, diagnostic microspheres, chromatography resins, protein purification, life sciences, affinity chromatography, ion exchange, molecular sieves, biomedical solutions, antibody purification, gene therapy, cell therapy, biological reagents, quality control products, biopharmaceuticals, macromolecule purification, medical device manufacturing, polymer material science, clinical laboratory medicine

Company overview

Changzhou Boyi Biotechnology company information

The essential company record, classifications and operating signals in one place.

Status
Operational
Founded
Headquarters
China
Employees
Open positions
None listed
Dealroom signal
11.7
client focusb2bindustryHealthsectorHard Tech

Valuation & funding

Changzhou Boyi Biotechnology funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AEquity / VC May 2023 $14M $55M Bangsheng Capital · Jinyu Bogor
Showing 1 recorded eventsUnlock the complete deal history →

Growth signals

Changzhou Boyi Biotechnology website traffic

Latest recorded traffic for Changzhou Boyi Biotechnology is 560 monthly website visits, up 833.3% over the last three months.

Latest monthly visits560 3-month web change+833.3%
Monthly website visits19 observations · Jun 2023–May 2026
Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Changzhou Boyi Biotechnology compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Showing 8 of the closest matchesCompare every metric →

Talent graph

Changzhou Boyi Biotechnology's talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

2 investors on Changzhou Boyi Biotechnology's cap table

Sourced from Dealroom's funding and investor records.

Series A 2 investors entered at this stage
Jinyu Bogor
Bangsheng Capital

Global footprint

Where Changzhou Boyi Biotechnology has talent and traffic

Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

In the news

Latest news about Changzhou Boyi Biotechnology

Recent press, funding announcements, and product moves mentioning Changzhou Boyi Biotechnology — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Changzhou Boyi Biotechnology

An AI-synthesized read of the highest-engagement posts about Changzhou Boyi Biotechnology on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Changzhou Boyi Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.